Clinical Trials

The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

Do you have coronary heart disease or are you healthy and would like to participate in research? This study is comparing how well two types of magnetic resonance imaging (MRI) scanners can detect different types of heart diseases, such as coronary heart disease, heart failure, congenital heart disease, and heart valve disease. The new type of MRI scanner in this study uses less energy than a traditional scanner and may be suitable for people who have metal devices in their bodies. This study is located in Bethesda, Maryland.

Are you interested in helping researchers understand what causes heart failure? The study is using a technique called magnetic resonance spectroscopy (MRS) during a cardiac magnetic resonance imaging (MRI) scan to determine whether energy metabolism is disrupted in heart failure and whether this contributes to poor heart function. To participate in this study, you must be at least 18 years old and either be healthy or have coronary artery disease, dilated cardiomyopathy, or left ventricular hypertrophy. The study is located in Baltimore, Maryland.

Are you at least 21 years old, and do you have heart failure? This study aims to better understand why heart failure can make it hard to exercise and perform daily activities. This complication is called exercise intolerance. Participants in the study will complete physical activities and then undergo magnetic resonance imaging (MRI) to look for changes in the chemicals the body uses for energy. To participate in this study, you must be at least 21 years old, diagnosed with heart failure, and be medically stable. This study is located in Baltimore, Maryland.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Are you able to have a magnetic resonance imaging (MRI) scan and want to help people with heart failure? This study is developing new methods for imaging the heart and blood vessels using MRI to improve how healthcare providers diagnose people with heart failure. This study takes place in Maryland and Washington, DC.

Are you an adult with heart failure with preserved ejection fraction (HFpEF), or do you just want to help individuals with this condition? This study is exploring why people with heart failure with preserved ejection fraction (HFpEF) have difficulty exercising and performing some activities of daily living. Researchers will use magnetic resonance imaging (MRI) of the heart and leg muscles to measure metabolites that serve as a source of energy for the body. To participate in this study, you must be 21 years or older. This study takes place in Baltimore, Maryland.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.